iifl-logo

Medico Intercontinental Ltd Management Discussions

Add as a Preferred Source on Google
₹23.18
(1.09%)
Nov 20, 2026|04:01:00 PM

Medico Intercontinental Ltd Share Price Management Discussions

In terms of Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 the Management Discussion and Analysis Report (MDAR) is structured as follows:

- Economic Outlook

- Industry structure and developments

- Opportunities

- Segment-wise or product-wise performance

- Outlook

- Threats, Risk and Concerns

- Internal Control System

- Financial and operational performance

- Material Development in Human Resources

- details of significant changes (i.e. change of 25% or more as compared to the immediately previous financial year) in key financial ratios, along with detailed explanations therefore, including:
(i) Debtors Turnover
(ii) Inventory Turnover
(iii) Interest Coverage Ratio
(iv) Current Ratio
(v) Debt Equity Ratio
(vi) Operating Profit Margin
(vii) Net Profit Margin
or sector-specific equivalent ratios, as applicable.

- details of any change in Return on Net Worth as compared to the immediately previous financial year along with a detailed explanation thereof.

Some Statements in this discussion may be forward looking. The Companys actual results, performance or achievements can thus differ materially from those projected in any such forward-looking statements in the management discussion and analysis on account of various factors such as changes in Government regulations, tax regimes, impact of competition, etc.

Economic Outlook:
Amid persistent global economic headwinds, India stands out as one of the fastest-growing major economies. According to the First Advance Estimates of Gross Domestic Product 2025-26, Indias GDP growth is projected at 7.4% in FY 2025-26, compared to 6.5% in FY 2024-25. Robust private consumption, tax reforms, and resilient manufacturing and services activity are supporting the growth trajectory. Despite rising trade tensions and policy uncertainty, Indias economic outlook remains resilient, with growth estimated at 6.5% in FY 2026-27 and 6.6% in FY 2027-28. Key drivers include easing inflationary pressures, rapid infrastructure development and digitization, a recovery in exports and private investments, and favorable policy reforms, among others.

Industry Structure and Developments:
Indian Pharmaceutical Industry
The Indian pharmaceutical industry was valued at approximately USD 55 billion in 2025 and is expected to reach USD 120-130 billion by 2030, growing at a CAGR of 11-13%. Growth will be driven by a combination of expanding healthcare access, growing demand for treatments across both acute and chronic conditions, digital transformation, and continued reliance on affordable generic medicines. India ranks as the third-largest pharmaceutical producer globally, by volume, and the 14th largest by value, contributing around 1.72% to Indias GDP. The strength of the industry lies in its well-established generics ecosystem, cost-effective manufacturing, and a large pool of skilled scientists and engineers. Indias pharmaceutical sector has a strong export presence, supplying medicines to over 200 countries worldwide, with the United States (US) being its largest export destination. Pharmaceutical exports have grown steadily from USD 15 billion in FY 2013-14 to USD 27.9 billion in FY 2023-24 and USD 30.47 billion in FY 2024-25. Generic drugs account for 20% of global exports in terms of volume, positioning the country as the largest provider of generic medicines globally.
In the Union Budget 2026-27, the government launched the Biopharma SHAKTI (Strategy for Healthcare Advancement), with an outlay of Rs. 10,000 crores over the next five years, aimed at positioning India as a global hub for biopharmaceutical manufacturing and innovation. This initiative reflects the growing shift in Indias disease burden toward non-communicable diseases, such as diabetes, underscoring the importance of biologic medicines in improving patient outcomes.
Looking ahead, the Indian Pharmaceutical industry is poised for robust growth, with the market projected to reach USD 450 billion by 2047. This expansion will be supported by favorable government policies, rising prevalence of chronic diseases, increasing foreign investments, and a strong focus on the manufacturing of high-quality pharmaceutical products.

GROWTH DRIVERS
Increase in Chronic Diseases: Rising incidences of chronic diseases such as hypertension, diabetes, respiratory ailments, and cardiovascular diseases on account of rapid urbanization, aging population, adoption of sedentary lifestyles, and poor dietary habits are expected to boost demand for pharmaceutical products.
Improving Affordability: Increasing income levels and affluence are prompting individuals to seek high-quality healthcare services, including better hospitals, medicines, and treatment.
Expanding Insurance Coverage: Health insurance penetration in India continues to deepen, supported by greater participation from private insurers and broader therapy coverage. The governments Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) health insurance scheme is driving healthcare access for patients.
Government Support and Incentives: Supportive government policies, such as the Production Linked Incentive (PLI) scheme, stringent quality and regulatory standards, and focus on chronic diseases, are further propelling the pharmaceutical industrys growth.

Company performance: Until the previous financial year, the Company was primarily engaged in the trading of pharmaceutical products. During the year under review, the Company expanded its business operations by acquiring a 51% equity stake in Calborn Lifescience Private Limited, thereby making it a subsidiary of the Company.
This strategic acquisition marks the Companys entry into the pharmaceutical manufacturing segment, strengthening its presence across the healthcare value chain. Calborn Lifescience Private Limited is engaged in the manufacturing of a unique portfolio of Vitamin D3 products and has established itself as one of the leading manufacturers in this niche segment. Notably, Calborn is recognized as the second manufacturer in India for this product category, providing the Company with a competitive advantage and opportunities for growth in the domestic and international markets.
The acquisition aligns with the Companys long-term strategy of diversifying its operations, enhancing value addition, and creating a stronger and more integrated business model. The Company expects this expansion into manufacturing to contribute positively to its future growth, profitability, and market positioning.
During the current financial year, the total income of the Company was Rs. 5680.62 Lakhs during current year as against Rs. 6763.75 Lakhs in the previous year. The Company has reported net profit of Rs. 218.36 Lakhs during the year under review as against profit of Rs. 256.58 Lakhs in the previous year. Your Board is looking more confident to increase revenue and profit in coming years.

Opportunities and Threats:
Being a Trading company, our company is exposed to specific risks that are particular to its business and the environment within which it operates including interest rate volatility, economic cycle, and market risk. Further, venturing into new verticals and products shall also expose your company to risk. However, these also give an opportunity to exponentially grow the business.

Business Performance:
During the current financial year, the total income of the Company was Rs. 5680.62 Lakhs during current year as against Rs. 6763.75 Lakhs in the previous year. The Company has reported net profit of Rs. 218.36 Lakhs during the year under review as against profit of Rs. 256.58 Lakhs in the previous year. Your Board is looking more confident to increase revenue and profit in coming years.

Outlook:
With the current promoters and management at the helm, your company is hopeful about the expansion of the business operations. Improving economic scenarios, growing consumption and demand shall create more opportunities.
It is expected that the economic conditions shall improve.

Risks and areas of concern:
Our strength is our determination and team work, weakness is the low equity base, opportunities are multiples and threats are the vibrations in the economy and government policies.
In any business, risks and prospects are inseparable. As a responsible management, the Companys principal Endeavour is to maximize returns. The Company continues to take all steps necessary to minimize its expenses through detailed studies and interaction with experts.

Internal control systems and their adequacy:
The Company has carried out the internal audit and has ensure that recording and reporting are adequate and proper, the internal controls exist in the system and that sufficient measures are taken to update the internal control system. The system also ensures that all transactions are appropriately authorized, recorded and reported. Exercises for safeguarding assets and protection against unauthorized use are undertaken from time to time. The Companys audit Committee reviewed the internal control system. All efforts are being made to make the internal control systems more effective. All these measures are continuously reviewed by the management and as and when necessary, improvements are affected.

Material developments in human resources/industrial relations front, including number of people employed:
The company had sufficient numbers of employees at its registered office. The company recognizes the importance of human value and ensures that proper encouragement both moral and financial is extended to employees to motivate them. The company enjoyed excellent relationship with workers and staff during the year under review.

details of significant changes (i.e. change of 25% or more as compared to the immediately previous financial year) in key financial ratios, along with detailed explanations therefore, including:
There were following changes in the below-mentioned ratios which may or may not be 25% or more as compared to the immediately previous financial year:
(i) Debtors Turnover – 2.68:1 as compared to 3.56:1 of previous year.
(ii) Inventory Turnover – 18.07:1 as compared to 14.93:1 of previous year.
(iii) Interest Coverage Ratio – 2.87:1 as compared to 6.32:1 of previous year.
(iv) Current Ratio – 2.37:1 as compared to 5.31:1 of previous year.
(v) Debt Equity Ratio – 0.65:1 as compared to 0.52:1 of previous year.
(vi) Operating Profit Margin (%) – 16.11% as compared to 16.47% of previous year.
(vii) Net Profit Margin (%) – 4.01% as compared to 3.82% of previous year.
or sector-specific equivalent ratios, as applicable.

details of any change in Return on Net Worth as compared to the immediately previous financial year along with a detailed explanation thereof – 0.09:1 as compared to 0.08:1 of previous year.

Cautionary Statement: Certain statements in the above Report may be forward looking and are stated as required by the legislations in force. The actual results may be affected by various factors that differ from what is anticipated in terms of future performance and the outlook presented above.

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited. All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.